Daniel L Sexton

US Patent:

7329737, Feb 12, 2008

Filed:

Aug 3, 2005

Appl. No.:

11/196627

Inventors:

Daniel J. Sexton - Melrose MA, US
Andrew Nixon - Hanover MA, US
Anthony Williams - Melrose MA, US
Robert C. Ladner - Ijamsville MD, US

Assignee:

Dyax Corp. - Cambridge MA

International Classification:

C07K 16/00
C07K 16/24
A61K 39/395

US Classification:

53038825, 5303881, 53038823, 4241301, 4241411, 4241451

Abstract:

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

US Patent:

7993646, Aug 9, 2011

Filed:

Dec 14, 2007

Appl. No.:

11/956792

Inventors:

Daniel J. Sexton - Melrose MA, US
Andrew Nixon - Hanover MA, US
Anthony Williams - Melrose MA, US
Robert C. Ladner - Ijamsville MD, US

Assignee:

Dyax Corp. - Cambridge MA

International Classification:

A61K 39/395

US Classification:

4241461, 4241301, 4241331, 4241411

Abstract:

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

US Patent:

20050100963, May 12, 2005

Filed:

Sep 11, 2003

Appl. No.:

10/661156

Inventors:

Aaron Sato - Somerville MA, US
Daniel Sexton - Melrose MA, US
Daniel Dransfield - Hanson MA, US
Robert Ladner - Ijamsville MD, US
Christophe Arbogast - Viuz - En - Sallaz, FR
Philippe Bussat - Feigers, FR
Hong Fan - Plainsboro NJ, US
Sudha Khurana - Plainsboro NJ, US
Karen Linder - Kingston NJ, US
Edmund Marinelli - Lawrenceville NJ, US
Palaniappa Nanjappan - Dayton NJ, US
Adrian Nunn - Lamberville NJ, US
Radhakrishna Pillai - Cranbury NJ, US
Sibylle Pochon - Troinex, CH
Ajay Shrivastava - Plainsboro NJ, US
Bo Song - Princeton NJ, US
Rolf Swenson - Princeton NJ, US
Mathew Von Wronski - Moorestown NJ, US

Assignee:

Dyax Corporation - Cambridge MA

International Classification:

G01N033/53
C07K007/64
A61K038/12

US Classification:

435007100, 514009000, 530317000

Abstract:

The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K

US Patent:

20050250700, Nov 10, 2005

Filed:

Sep 13, 2004

Appl. No.:

10/939890

Inventors:

Aaron Sato - Somerville MA, US
Daniel Sexton - Melrose MA, US
Daniel Dransfield - Hanson MA, US
Robert Ladner - Ijamsville MD, US
Christophe Arbogast - Viuz-En-Sallaz, FR
Phillipe Bussat - Feigers, FR
Hong Fan - Plainsboro NJ, US
Sudha Khurana - Plainsboro NJ, US
Karen Linder - Kingston NJ, US
Edmund Marinelli - Lawrenceville NJ, US
Palaniappa Nanjappan - Dayton NJ, US
Adrian Nunn - Lamberville NJ, US
Radhakrishna Pillai - Cranbury NJ, US
Sibylle Pochon - Troinex, CH
Ajay Shrivastava - Plainsboro NJ, US
Bo Song - Princeton NJ, US
Rolf Swenson - Princeton NJ, US
Mathew Von Wronski - Moorestown NJ, US

International Classification:

A61K038/10
C07K007/08

US Classification:

514015000, 530329000

Abstract:

The present invention provides, inter alia, peptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K

US Patent:

20110200611, Aug 18, 2011

Filed:

Jan 6, 2011

Appl. No.:

12/985914

Inventors:

Daniel J. Sexton - Melrose MA, US

Assignee:

DYAX CORP. - Cambridge MA

International Classification:

A61K 39/395
C07K 16/40
A61P 1/00
A61P 19/02
A61P 25/04
A61P 29/00
A61P 11/00
A61P 9/00

US Classification:

4241581, 5303893, 5303871

Abstract:

Plasma kallikrein binding proteins and methods of using such proteins are described.

US Patent:

20120027686, Feb 2, 2012

Filed:

Jul 28, 2011

Appl. No.:

13/192786

Inventors:

Daniel J. Sexton - Melrose MA, US
Andrew Nixon - Hanover MA, US
Anthony Williams - Melrose MA, US
Robert C. Ladner - Ijamsville MD, US

Assignee:

DYAX CORP. - Cambridge MA

International Classification:

A61K 39/395
C12N 15/13
A61P 11/00
C12N 1/19
C40B 40/10
C12N 15/62
C12N 15/81
A61K 49/16
G01N 33/573

US Classification:

424 93, 4241581, 4241331, 536 2353, 435 71, 506 18, 536 234, 4353201, 4352542

Abstract:

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

US Patent:

20120201756, Aug 9, 2012

Filed:

Jan 6, 2012

Appl. No.:

13/345170

Inventors:

Daniel J. Sexton - Melrose MA, US

Assignee:

DYAX CORP. - Cambridge MA

International Classification:

A61K 39/395
A61K 49/00
A61P 43/00
A61P 19/02
A61P 37/00
A61P 19/06
A61P 1/00
A61P 29/00
A61P 25/00
A61P 19/00
A61P 7/02
A61P 9/00
A61P 9/10
A61P 13/12
A61P 17/02
A61P 11/00
C07K 16/40

US Classification:

424 91, 5303893, 4241581

Abstract:

Plasma kallikrein binding proteins and methods of using such proteins are described.

US Patent:

20220223299, Jul 14, 2022

Filed:

May 22, 2020

Appl. No.:

17/613465

Inventors:

- Osaka, JP
Hoa Q. Nguyen - Lynnfield MA, US
Daniel J. Sexton - Melrose MA, US

Assignee:

Takeda Pharmaceutical Company Limited - Osaka

International Classification:

G16H 70/60
G16H 50/50
G16H 50/30

Abstract:

Aspects of the present application provide for methods and apparatuses for modeling, simulating, and treating hereditary angioedema (HAE). According to some aspects, a quantitative systems pharmacology (QSP) model is provided for simulating the efficacy of drug intervention under context of HAE pathophysiology. The QSP model may comprise a plurality of individual models including one or more PK models and/or one or more PD models for simulating drug exposure, target engagements and acute attack rate in HAE patients. A virtual patient population representing a plurality of virtual patients may be developed and input into the QSP model for executing a virtual clinical trial. In some embodiments, the QSP model may be used evaluate a response of the contact system and/or an effectiveness of a therapeutic intervention for treating HAE.